[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635424":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":11,"centralContacts":23,"locations":29,"responsibleParty":99,"collaborators":101,"id":109,"slug":11,"hasResults":110,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":11,"eligibilityCriteria":113,"healthyVolunteers":110,"sex":114,"minAge":115,"maxAge":116,"enrollmentInfo":117,"targetDuration":11,"studyType":120,"phases":121,"briefSummary":123,"conditions":124,"keywords":128,"overallStatus":132,"whyStopped":11,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":142},{"fullName":5,"class":6},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Goserelin group","EXPERIMENTAL",null,[13],"Drug: Goserelin Depot",{"label":15,"type":16,"description":11,"interventionNames":11},"Control group","NO_INTERVENTION",[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":11},"DRUG","Goserelin Depot","Subcutaneous injection of 3.6 mg of goserelin acetate once, administered 1 to 3 days prior to allogeneic haematopoietic stem cell transplantation conditioning.",[9],[24],{"name":25,"role":26,"phone":27,"phoneExt":11,"email":28},"wei shi","CONTACT","86-13207131315","496020121@qq.com",[30,47,62,69,84],{"facility":31,"status":11,"city":32,"state":33,"zip":34,"country":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"The First Affiliated Hospital of Zhengzhou University","Zhengzhou","Henan","450000","China",{"type":37,"coordinates":38},"Point",[39,40],113.64861,34.75778,{"lat":40,"lon":39},[43],{"name":44,"role":26,"phone":45,"phoneExt":11,"email":46},"jie wei Cao","86-15093360671","15093360671@163.com",{"facility":48,"status":11,"city":49,"state":50,"zip":51,"country":35,"cosmosGeoPoint":52,"geoPoint":56,"contacts":57},"Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Wuhan","Hubei","430000",{"type":37,"coordinates":53},[54,55],114.26667,30.58333,{"lat":55,"lon":54},[58],{"name":59,"role":26,"phone":60,"phoneExt":11,"email":61},"yang Cao","86-13986142606","13986142606@163.com",{"facility":5,"status":11,"city":49,"state":50,"zip":51,"country":35,"cosmosGeoPoint":63,"geoPoint":65,"contacts":66},{"type":37,"coordinates":64},[54,55],{"lat":55,"lon":54},[67],{"name":68,"role":26,"phone":27,"phoneExt":11,"email":28},"wei Shi",{"facility":70,"status":11,"city":71,"state":72,"zip":73,"country":35,"cosmosGeoPoint":74,"geoPoint":78,"contacts":79},"The First People's Hospital of Yunnan Province","Kunming","Yunnan","650000",{"type":37,"coordinates":75},[76,77],102.71833,25.03889,{"lat":77,"lon":76},[80],{"name":81,"role":26,"phone":82,"phoneExt":11,"email":83},"jie ya Wang","86-13211630338","13211630338@163.com",{"facility":85,"status":11,"city":86,"state":87,"zip":88,"country":35,"cosmosGeoPoint":89,"geoPoint":93,"contacts":94},"The First Affiliated Hospital, Zhejiang University School of Medicine","Hangzhou","Zhejiang","310000",{"type":37,"coordinates":90},[91,92],120.16142,30.29365,{"lat":92,"lon":91},[95],{"name":96,"role":26,"phone":97,"phoneExt":11,"email":98},"min yan Zhao","86-15858199217","15858199217@163.com",{"type":100,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[102,104,106,107],{"name":103,"class":6},"Wuhan TongJi Hospital",{"name":105,"class":6},"Zhejiang University",{"name":31,"class":6},{"name":108,"class":6},"The First People's Hospital of Yunnan","100635424",false,"NCT07552506","Clinical Study on the Preservation of Ovarian Function in Patients With Aplastic Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation Using Goserelin","Inclusion Criteria:\n\n(1) Patients clinically diagnosed with SAA and scheduled for allogeneic haematopoietic stem cell transplantation (allo-HSCT); (2) Female patients aged 14 to 50 years, within reproductive age, with regular menstrual cycles prior to transplantation; (3) Patients or their legal representatives voluntarily participate and sign informed consent forms, demonstrating comprehension and willingness to comply with all study procedures and requirements; (4) Patients with an estimated survival period exceeding one year to ensure sufficient time for monitoring menstrual recovery.\n\nExclusion Criteria:\n\n(1) Patients with severe dysfunction of vital organs such as the heart, liver, or kidneys, which may compromise study outcomes or increase patient risk; (2) Patients with a history of allergy to goserelin or related medications; (3) Patients who have previously undergone menopause due to physiological or pathological factors; (4) Patients with a history of gynaecological conditions (e.g., polycystic ovary syndrome, endometriosis) that may interfere with the assessment of menstrual recovery; (5) Patients currently participating in other clinical studies that may influence menstrual recovery; (6) Patients who refuse to participate in this clinical study.","FEMALE","14 Years","50 Years",{"count":118,"type":119},132,"ESTIMATED","INTERVENTIONAL",[122],"NA","This study is a prospective, randomized, controlled, multicenter clinical trial. It plans to enroll 132 female SAA patients aged 14-50 years from multiple medical centers nationwide who are scheduled to undergo allo-HSCT. Patients will be divided into two groups based on whether they receive busulfan conditioning: the busulfan-conditioned group (Bu group) and the non-busulfan-conditioned group (non-Bu group). Within each group, patients will be randomly assigned 1:1 to either the experimental group (Goserelin prophylaxis group) or the control group using a random number table. The experimental group will receive a single 3.6 mg subcutaneous injection of Goserelin 1-3 days prior to conditioning, in addition to the standard transplantation regimen. The control group will not receive Goserelin prophylaxis. The primary endpoint was menstrual recovery rate at 6 months post-transplant (defined as ≥3 naturally occurring menstrual cycles without intervention by menstrual-regulating drugs). Secondary endpoints included: incidence of premature ovarian insufficiency (POI); ovarian reserve function markers: anti-Müllerian hormone (AMH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2) levels; Additional reproductive parameters: ovarian and uterine volume, endometrial thickness; time to neutrophil\u002Fplatelet engraftment; incidence of acute\u002Fchronic graft-versus-host disease (aGVHD\u002FcGVHD), EBV\u002FCMV infection rates; transplant-related mortality; and adverse event (AE) occurrence. This study aims to evaluate the efficacy and safety of goserelin in preserving ovarian function following allo-HSCT.",[125,126,127],"Aplastic Anaemia (AA)","Allogeneic Haematopoietic Stem Cell Transplantation","Ovarian Insufficiency",[129,130,131],"Aplastic anaemia","Allogeneic haematopoietic stem cell transplantation","Ovarian insufficiency","NOT_YET_RECRUITING","2026-04-20",{"date":135,"type":136},"2026-04-27","ACTUAL",{"date":138,"type":119},"2026-05-01",{"date":140,"type":119},"2027-10-01",{"name":5,"class":6},5]